OC
OCGN.US Ocugen Inc
- Market cap
- USD 281M
- P/E
- -
- P/B
- 75.94x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OCGN.US undervalued?
Graham numberThe Graham number of Ocugen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ocugen Inc fundamental analysis
No fundamental analysis for Ocugen Inc yet.
Ocugen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the…
Full company profileOcugen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ocugen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 42.6K | 43.0K | 22.9K | 2.49M | 6.04M | 4.06M | 4.41M | 6.63M |
| Gross Profit | -1.67M | -1.53M | -49.6K | -8.09M | -6.31M | -589K | -1.07M | 5.33M | 2.09M | 2.02M | 5.90M |
| Operating Income | -30.3M | -25.0M | -30.1M | -14.2M | -21.3M | -58.0M | -84.9M | -65.5M | -54.8M | -62.9M | -69.4M |
| EBITDA | -11.4M | -24.9M | -14.4M | -14.1M | -14.2M | -58.1M | -84.4M | -62.4M | -52.1M | -60.3M | -72.4M |
| Net Income | -16.2M | -26.4M | -8.64M | -20.2M | -21.8M | -58.4M | -77.8M | -63.1M | -54.1M | -67.8M | -63.5M |
| EPS | -68 | -70 | -14 | -1.46 | -0.19 | -0.30 | -0.36 | -0.26 | -0.20 | -0.23 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 36.1M | 11.0M | 17.4M | 16.8M | 27.4M | 106M | 109M | 64.5M | 82.4M | 43.5M | 108M |
| Total Liabilities | 22.5M | 22.3M | 17.9M | 5.79M | 5.83M | 9.94M | 34.7M | 24.0M | 52.8M | 55.7M | 126M |
| Shareholders' Equity | 13.6M | -11.3M | -458K | 11.0M | 21.6M | 95.8M | 74.0M | 40.6M | 29.6M | -12.2M | -17.7M |
| Cash & Short-term Investments | 31.9M | 7.98M | 15.5M | 7.44M | 24.0M | 95.0M | 90.9M | 39.5M | 58.5M | 18.6M | 84.3M |
| Total Debt | 761K | 178K | 238K | 1.41M | 2.49M | 3.31M | 6.37M | 6.94M | 32.5M | 33.1M | 88.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.7M | -23.0M | -15.8M | -16.9M | -14.7M | -47.9M | -60.1M | -62.1M | -42.1M | -57.0M | -66.3M |
| Capital Expenditure | 320K | 276K | 2.01M | 29.4K | 307K | 939K | 4.46M | 10.5M | 3.39M | 185K | 235K |
| Free Cash Flow | -26.1M | -23.3M | -17.8M | -16.9M | -15.0M | -48.9M | -64.5M | -72.5M | -45.5M | -57.1M | -66.5M |
| Ratios | |||||||||||
| ROE | -119.5% | - | - | -183.7% | -101.3% | -60.9% | -105.2% | -155.5% | -182.4% | - | - |
| ROA | -44.9% | -239.4% | -49.6% | -120.4% | -79.7% | -55.2% | -71.6% | -97.7% | -65.6% | -155.9% | -58.8% |
| Net Profit Margin | - | - | - | -47,496.5% | -50,748.8% | -254,646.6% | -3,128.4% | -1,045.0% | -1,333.0% | -1,537.4% | -958.4% |
| Debt to Equity | 0.06x | - | - | 0.13x | 0.12x | 0.03x | 0.09x | 0.17x | 1.10x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ocugen Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 6.80M | 0.49 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:60 on Sep 30, 2019.
Who owns Ocugen Inc
- Insiders 3.81%
- Institutions 41.31%
- Public & others 54.89%
- Shares outstanding 339M
- Free float 334M
Top funds holding OCGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 11.6M | 3.43% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 10.2M | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 8.72M | 2.57% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 3.76M | 1.11% | +1.41% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 2.24M | 0.66% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 1.99M | 0.59% | +1.20% | Sep 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 1.82M | 0.54% | +0.08% | Oct 2026 |
| Fidelity Extended Market Index | 1.14M | 0.34% | -32.16% | Sep 2026 |
| iShares Micro-Cap ETF | 1.04M | 0.31% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 1.00M | 0.29% | +0.11% | Sep 2026 |
| iShares Russell 2000 Value ETF | 996K | 0.29% | 0.00% | Oct 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 963K | 0.28% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 831K | 0.24% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 669K | 0.20% | +0.03% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 639K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 620K | 0.18% | -0.05% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 532K | 0.16% | +164.71% | Aug 2026 |
| Fidelity Series Total Market Index | 518K | 0.15% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 506K | 0.15% | -5.90% | Oct 2026 |
| Direxion Daily S&P Biotech Bull 3X ETF | 476K | 0.14% | 0.00% | Oct 2026 |
Top institutions holding OCGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 27.0M | 7.96% | +269.65% | Jun 2026 |
| State Street Corp | 21.5M | 6.33% | +122.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 14.4M | 4.24% | +4.12% | Jun 2026 |
| Millennium Management LLC | 13.9M | 4.11% | +1.57% | Jun 2026 |
| Geode Capital Management, LLC | 8.87M | 2.61% | +109.86% | Jun 2026 |
| RTW INVESTMENTS, LLC | 6.67M | 1.96% | 0.00% | Jun 2026 |
| UBS Group AG | 5.18M | 1.53% | -28.88% | Jun 2026 |
| Ikarian Capital, LLC | 3.96M | 1.17% | 0.00% | Jun 2026 |
| GMT Capital Corp | 3.51M | 1.03% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 3.41M | 1.01% | -57.65% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.33M | 0.98% | +255.79% | Jun 2026 |
| Hennion & Walsh Asset Management Inc | 2.83M | 0.83% | +121.69% | Jun 2026 |
| Northern Trust Corp | 2.75M | 0.81% | +284.95% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.37M | 0.70% | +18.29% | Jun 2026 |
| Two Sigma Investments LLC | 2.23M | 0.66% | -0.94% | Jun 2026 |
| Qube Research & Technologies | 2.20M | 0.65% | -41.60% | Jun 2026 |
| Bank of America Corp | 1.99M | 0.59% | +69.53% | Jun 2026 |
| HRT FINANCIAL LLC | 1.77M | 0.52% | +369.55% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.10M | 0.32% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.04M | 0.31% | +391.54% | Jun 2026 |
Ocugen Inc company profile
- Company name
- Ocugen Inc
- Ticker
- OCGN.US
- Exchange
- USA Stocks
- Listed since
- Dec 3, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 116
- Fiscal year end
- December
- Address
- 11 Great Valley Parkway, Malvern, PA, United States, 19355
- Phone
- 484 328 4701
- Website
- ocugen.com
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen Inc management
10- Dr. Shankar Musunuri M.B.A., Ph.D.Co-Founder, CEO & Chairman · born 1964
- Dr. Arun Upadhyay Ph.D.Chief Scientific Officer and Head of Research & Development · born 1982
- Ms. Rita Johnson-Greene M.B.A.CFO & Principal Accounting Officer · born 1977
- Mr. Paul StaidExecutive Vice President of Operations
- John Kouch J.D.General Counsel
- Mr. Chris ClarkVP of Corporate Communications
- Ms. Kristen CraftHead of People & Culture
- Dr. Vijay Tammara Ph.D.Chief Development Officer · born 1960
- Dr. Mohamed Genead M.D., M.Sc.Chief Medical Officer
- Ms. Jyothy Pillai M.S.VP & Head of Regulatory & Quality